---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Heterogeneity of treatment effect"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Heterogeneity of treatment effect. Topics: Palazestrant phase 2 results by ESR1 status at 120 mg (OP-1250-001), Palazestrant results by ESR1 status in the second- and third-line subset (OP-1250-001), Palazestrant plus ribociclib by ESR1 status after a prior CDK4/6 inhibitor (OP-1250-003), Investigator interpretation of ESR1-dependent benefit across the class, and 12 further topics. 16 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Palazestrant phase 2 results by ESR1 status at 120 mg (OP-1250-001)

> “Across all 86 patients, the median progression-free survival (PFS) was 4.6 months and the clinical benefit rate (CBR), was 40% with a 6-month PFS rate of 38%. In patients with an ESR1 mutation, the median PFS was 5.6 months and the CBR was 52% with a 6-month PFS rate of 46%. In ESR1 wild-type patients, the median PFS was 3.5 months and the CBR was 32% with a 6-month PFS rate of 35%.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.2.2.3-2"></a>

### Palazestrant results by ESR1 status in the second- and third-line subset (OP-1250-001)

> “In a subset analysis of 49 patients that received palazestrant as a second- or third-line therapy with or without prior chemotherapy, the median PFS was 7.2 months and the CBR was 48% across all patients with a 6-month PFS rate of 54%. In patients with an ESR1 mutation, the median PFS was 7.3 months and CBR was 59% with a 6-month PFS rate of 62%. In ESR1 wild-type patients the median PFS was 5.5 months and the CBR was 38% with a 6-month PFS rate of 44%.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.2.2.3-3"></a>

### Palazestrant plus ribociclib by ESR1 status after a prior CDK4/6 inhibitor (OP-1250-003)

> “Median PFS was 12.2 months for those who received prior treatment with CDK4/6i, including 9.2 months for patients with ESR1 wild-type tumors and 13.8 months for patients with tumors with ESR1 mutations.”

Source: [Olema Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107169/olma-20251231.htm)

<a id="topic-2.2.2.3-4"></a>

### Investigator interpretation of ESR1-dependent benefit across the class

> “Recent studies showed that imlunestrant may be beneficial only for cancers harboring ESR1 mutations”
> “Limitations of this study, as with most early-phase clinical trials, include its open-label design and lack of a comparator arm that limit the interpretation of the observed safety profile and antitumor activity.”

Source: [Hamilton et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210654/)

<a id="topic-2.2.2.3-5"></a>

### Elacestrant in tumors without a detected ESR1 mutation (EMERALD, FDA review)

> “In an exploratory analysis of PFS in the ESR1-mut-nd subgroup, the HR was 0.86 (95% CI, 0.63 to 1.19), with the median PFS of 1.9 months (95% CI, 1.9 to 3.6) in the elacestrant arm and 2.0 months (95% CI, 1.9 to 2.2) in the SOC arm.”
> “By contrast, the benefit-risk assessment in patients without ESR1 mutations was not favorable.”

Source: [Shah et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11003513/)

<a id="topic-2.2.2.3-6"></a>

### Imlunestrant by ESR1 status (EMBER-3)

> “In exploratory analyses involving patients without ESR1 mutations, the median progression-free survival was 5.6 months in the imlunestrant group and 5.7 months in the standard-therapy group (hazard ratio for progression or death, 1.00; 95% CI, 0.79 to 1.27)”
> “In addition, the treatment effect of imlunestrant–abemaciclib was similar in patients with or without ESR1 or PI3K pathway mutations.”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.3-7"></a>

### Vepdegestrant by ESR1 status (VERITAC-2)

> “Among all the patients, the median progression-free survival was 3.8 months (95% CI, 3.7 to 5.3) with vepdegestrant and 3.6 months (95% CI, 2.6 to 4.0) with fulvestrant (hazard ratio, 0.83 [95% CI, 0.69 to 1.01]; P = 0.07).”
> “Among patients with ER-positive, HER2-negative advanced breast cancer, vepdegestrant was associated with significantly longer progression-free survival than fulvestrant in the subgroup with ESR1 mutations but not in the full patient population.”

Source: [Campone et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40454645/)

<a id="topic-2.2.2.3-8"></a>

### Giredestrant plus everolimus by ESR1 status (evERA)

> “Among 207 patients with ESR1 -mutated tumors, median progression-free survival was 10.0 months with giredestrant-everolimus and 5.5 months with standard endocrine therapy-everolimus (hazard ratio [HR], 0.38; 95% confidence interval [CI], 0.27 to 0.54; P<0.001). In the overall study population, median progression-free survival was 8.8 versus 5.5 months, respectively (HR, 0.56; 95% CI, 0.44 to 0.71; P<0.001).”

Source: [Mayer et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674676/)

<a id="topic-2.2.2.3-9"></a>

### Consistency of oral SERD hazard ratios in ESR1-mutated tumors

> “Across this body of evidence, a consistent pattern emerges of modest absolute clinical benefit in ESR1-mutated tumors, with hazard ratios generally in the 0.55–0.62 range.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.3-10"></a>

### Duration of prior endocrine therapy plus CDK4/6 inhibitor (EMERALD)

> “In patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months, the median PFS for elacestrant versus SOC was 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26–0.63).”
> “The P value for interaction between elacestrant treatment and prior ET+CDK4/6i duration (<12 vs. ≥12 months) was statistically significant”
> “Prior ET+CDK4/6i ≥12 months may help identify patients with ESR1-mutated tumors that remain endocrine-sensitive to elacestrant, enabling ET sequencing in the second line before other targeted therapies and drug combinations, and may delay chemotherapy-based regimens, including antibody–drug conjugates.”

Source: [Bardia et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443208/)

<a id="topic-2.2.2.3-11"></a>

### PIK3CA co-mutation with ESR1 mutation (EMERALD)

> “Among patients with PIK3CA- and ESR1-mutated tumors, the mPFS with elacestrant was 5.5 versus 1.9 months with SOC (HR, 0.42; 95% CI, 0.18–0.94).”

Source: [Bardia et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443208/)

<a id="topic-2.2.2.3-12"></a>

### Concurrent ESR1 and PI3K pathway mutations with elacestrant in routine practice

> “Disease with dual ESR1 and PI3K pathway mutations (PIK3CA, AKT1, and PTEN) had a median TTNT of 5.2 months.”
> “Higher ESR1 polyclonality (≥4 alterations; 11% of patients) correlated with a shorter TTNT of 5.2 months (hazard ratio, 1.44; 95% confidence interval, 1.01–2.06), but efficacy was consistent across ESR1 alleles (e.g., Y537S and D538G).”

Source: [Lloyd et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12770935/)

<a id="topic-2.2.2.3-13"></a>

### Visceral and bone metastases (EMERALD)

> “ESR1 mutations are associated with visceral metastases and endocrine resistance”
> “In this population, the median PFS (in months) for elacestrant versus SOC was 9.1 versus 1.9 (bone metastases), 7.3 versus 1.9 (liver and/or lung metastases)”

Source: [Bardia et al. (2024a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11443208/)

<a id="topic-2.2.2.3-14"></a>

### Visceral and liver metastases with elacestrant in routine practice

> “In patients with coexisting ESR1- and PI3K-pathway–mutated tumors, mTTNT was 6.3 months (95% CI, 4.8–7.9).”
> “mTTNT was 7.9 months (95% CI, 7.1–9.8) in all patients and was also sustained in patients with no prior fulvestrant [12.9 months (95% CI, 7.2–not reached)], no prior chemotherapy [8.4 months (95% CI, 7.1–13.3)], visceral metastasis [7.9 months (95% CI, 7.0–9.9)], and liver metastases [7.2 months (95% CI, 6.3–9.0)].”

Source: [Rugo et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12770937/)

<a id="topic-2.2.2.3-15"></a>

### Abemaciclib plus fulvestrant across ESR1 and PIK3CA subgroups (postMONARCH)

> “Consistent abemaciclib treatment effect was observed across the most prevalent biomarker subgroups”
> “HR, 0.79 (95% CI, 0.54 to 1.15) ESR1 detected versus 0.78 (95% CI, 0.54 to 1.12) not detected; HR, 0.76 (95% CI, 0.50 to 1.14) PIK3CA detected versus 0.80 (95% CI, 0.57 to 1.12) not detected.”

Source: [Kalinsky et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11936477/)

<a id="topic-2.2.2.3-16"></a>

### ESR1 mutation prevalence by line of therapy

> “ESR1mut was found in 8.1% TBx, 17.5% LBx TF ≥ 1%, and 4.9% LBx TF < 1% in 1st line, increasing to 59% in 3rd line (LBx TF ≥ 1%).”
> “Patients receiving 1st-line aromatase inhibitor + CDK4/6 inhibitor (n = 573) with ESR1mut had less favorable rwPFS and rwOS versus ESR1 wild-type; no differences were observed for fulvestrant + CDK4/6 inhibitor (n = 348).”

Source: [Bhave et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11420341/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
